CalciMedica (CALC) Competitors $3.09 -0.08 (-2.52%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CALC vs. CKPT, IPHA, PBYI, CDTX, BMEA, ADAP, RENB, FATE, STRO, and TCRXShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Checkpoint Therapeutics (CKPT), Innate Pharma (IPHA), Puma Biotechnology (PBYI), Cidara Therapeutics (CDTX), Biomea Fusion (BMEA), Adaptimmune Therapeutics (ADAP), Renovaro (RENB), Fate Therapeutics (FATE), Sutro Biopharma (STRO), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Checkpoint Therapeutics Innate Pharma Puma Biotechnology Cidara Therapeutics Biomea Fusion Adaptimmune Therapeutics Renovaro Fate Therapeutics Sutro Biopharma TScan Therapeutics Checkpoint Therapeutics (NASDAQ:CKPT) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking. Is CKPT or CALC more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% CalciMedica N/A -164.24%-103.53% Which has more volatility and risk, CKPT or CALC? Checkpoint Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Do insiders & institutionals have more ownership in CKPT or CALC? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in CKPT or CALC? Checkpoint Therapeutics received 165 more outperform votes than CalciMedica when rated by MarketBeat users. However, 93.75% of users gave CalciMedica an outperform vote while only 67.42% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% CalciMedicaOutperform Votes1593.75% Underperform Votes16.25% Which has better valuation and earnings, CKPT or CALC? CalciMedica has lower revenue, but higher earnings than Checkpoint Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$100K1,552.79-$51.85M-$1.84-1.73CalciMedicaN/AN/A-$34.36M-$1.08-2.86 Does the media favor CKPT or CALC? In the previous week, Checkpoint Therapeutics had 3 more articles in the media than CalciMedica. MarketBeat recorded 4 mentions for Checkpoint Therapeutics and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.50 beat Checkpoint Therapeutics' score of 0.28 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Checkpoint Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CKPT or CALC? Checkpoint Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 277.36%. CalciMedica has a consensus target price of $19.33, suggesting a potential upside of 525.67%. Given CalciMedica's higher probable upside, analysts plainly believe CalciMedica is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCheckpoint Therapeutics and CalciMedica tied by winning 7 of the 14 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.65M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-2.869.8789.3417.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book2.186.055.314.79Net Income-$34.36M$154.90M$122.54M$225.00M7 Day Performance6.55%-0.32%0.59%2.62%1 Month Performance11.96%0.43%2.55%3.81%1 Year Performance-35.37%3.08%25.29%20.10% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.3838 of 5 stars$3.09-2.5%$19.33+525.7%-35.4%$41.65MN/A-2.8630Short Interest ↓CKPTCheckpoint Therapeutics3.6277 of 5 stars$3.17+0.3%$12.00+278.5%+72.8%$154.80M$47,000.00-1.7210Short Interest ↑News CoveragePositive NewsIPHAInnate Pharma3.325 of 5 stars$1.84+4.0%$11.50+525.0%-35.2%$152.36M$24.85M0.00220Analyst ForecastNews CoveragePositive NewsPBYIPuma Biotechnology4.0217 of 5 stars$3.08-6.9%$7.00+127.3%-36.9%$151.19M$243.57M6.42200CDTXCidara Therapeutics3.9735 of 5 stars$21.40-10.8%$32.20+50.5%+51.6%$150.81M$44.65M-0.8490BMEABiomea Fusion2.9586 of 5 stars$4.16+4.5%$39.36+846.2%-71.5%$150.75MN/A-1.0450ADAPAdaptimmune Therapeutics2.3847 of 5 stars$0.59-5.6%$2.79+376.5%-17.5%$149.69M$175.04M-2.66449Short Interest ↑RENBRenovaro0.7747 of 5 stars$0.92+16.5%N/A-85.2%$146.51MN/A-0.9620FATEFate Therapeutics4.6845 of 5 stars$1.28-12.4%$6.75+426.2%-72.0%$146.12M$13.45M-0.78550Short Interest ↓Positive NewsSTROSutro Biopharma4.3982 of 5 stars$1.76-4.9%$11.13+532.1%-50.5%$145.13M$160.96M-1.09240TCRXTScan Therapeutics2.4048 of 5 stars$2.68-3.2%$11.25+319.8%-55.5%$143.03M$9.36M-2.53100 Related Companies and Tools Related Companies Checkpoint Therapeutics Alternatives Innate Pharma Alternatives Puma Biotechnology Alternatives Cidara Therapeutics Alternatives Biomea Fusion Alternatives Adaptimmune Therapeutics Alternatives Renovaro Alternatives Fate Therapeutics Alternatives Sutro Biopharma Alternatives TScan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALC Stock Alerts